An Early Phase 1 interventional study of Beetroot extract and Placebo in Arterial Hypertension, Resistant Hypertension and Microvascular Function, sponsored by National Institute of Cardiology, Laranjeiras, Brazil. Recruiting at 1 site in Brazil. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by National Institute of Cardiology, Laranjeiras, Brazil · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 209 studies in Hypertension with a site in Brazil — 28 open to participants now, 33 under way, 6 of them phase 3. Hypertension · Brazil.
Among the 209 studies in Hypertension with a site in Brazil, this one is the 123rd largest by planned enrollment of the 189 interventional ones that give a count, is one of 6 that started in 2023, is one of 2 in phase 1, reaches primary completion later than 10 of the 32 other live ones, and was the 173rd registered.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
Browse Hypertension studies →28 of the 209 studies in Hypertension with a site in Brazil are open now. Recruiting first, the newest first:
University of Nove de Julho · Sites in Brazil
Ages 18–65
AstraZeneca · Sites in Brazil
Ages 18+
Instituto Dante Pazzanese de Cardiologia · Sites in Brazil
Ages 18+
Raphael Mendes Ritti Dias · Sites in Brazil
Ages 60+
Universidade Federal Fluminense · Sites in Brazil
Ages 18–75
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
209 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 7 · Phase 3 40 · Phase 4 31
First in 1999; this study’s year is marked. 6 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 80 across the 189 interventional studies, 127 across the 18 observational. Of the 136 that completed or were terminated, 20 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 209 have an industry lead sponsor. The 10 most frequent:
National Institute of Cardiology, Laranjeiras, Brazil is the lead sponsor of 21 studies on the registry; 4 are open to participants now.
National Institute of Cardiology, Laranjeiras, Brazil has 5 studies filed under Hypertension — fewer than ten, so there is no comparison to draw.
18 of the studies in Hypertension with a site in Brazil that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT07361276AstraZenecaObservational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care System | 2026-11-30 |
| NCT06105775University of Sao PauloInorganic Nitrate Supplementation in Chronic Hypertensive Pregnancies | 2026-12 |
| NCT06169241National Institute of Cardiology, Laranjeiras, BrazilEffect of Nitrate Supplementation on Blood Pressure and Microvascular Function of Resistant Hypertensive Patients | 2026-12 |
| NCT06917131Universidade Federal FluminenseRoyal Jelly as a Strategy to Modulate Inflammation and Oxidative Stress in Patients With Systemic Arterial Hypertension | 2026-12-10 |
Add all 18 to your calendar (.ics) → With an account.
Among the 209 studies in Hypertension with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Arterial hypertension (AH) has been identified as an important public health problem and considered a new epidemic with high mortality and morbidity. High blood pressure (BP) levels increase the chances of coronary artery disease (CAD), heart failure (HF), stroke, chronic renal failure (CRF) and death. Beetroot powder may be an easier way to increase the availability of nitric oxide and consequently vasodilation in these patients. However, studies are needed to evaluate its benefits in patients with AH.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The placebo group will be administered as a colored and flavored isocaloric supplement composed of maltodextrin.
Dietary Supplement: Placebo
Beetroot extract powder supplementation with 400mg of nitrate per dose in the amount of 10g per day orally will be used in the group.
Dietary Supplement: Beetroot extract
Beetroot extract powder supplementation with 400mg of nitrate per dose in the amount of 10g per day orally will be used in the group.
The placebo will be administered as a colored and flavored isocaloric supplement composed of maltodextrin.
Assessment of blood pressure evolution
Evaluation using Ambulatory Blood Pressure Monitoring: systolic, diastolic and mean arterial pressures
Time frame: 60 days
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2023 (actual). Primary completion is estimated for Dec 2026, 37 months after the start.
Of 44 non-industry phase 1 interventional studies under Hypertension, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 12. This study's planned 37 months is close to that.
Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 1 and three quarters within 18.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Institute of Cardiology, Laranjeiras, Brazil